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Zusammenfassung
Die Diagnostik und Behandlung der chronischen lympha-
tischen Leukämie (CLL) ist derzeit starken Änderungen
unterworfen. Neue Erkenntnisse zu Prognosefaktoren
und neue Therapieverfahren wie Purinanaloga, Hochdo-
sistherapie und monoklonale Antikörper trugen wesent-
lich zu diesem Fortschritt bei. Die Behandlung der CLL
ist heute wesentlich differenzierter zu sehen als noch vor
wenigen Jahren und erfordert eine alters- und risikoan-
gepasste Vorgehensweise. Es ist gleichzeitig zu betonen,
dass noch viele wesentliche Fragen zur Therapie der CLL
offen sind. Nur durch Behandlung der Patienten im Rah-
men von multizentrischen Studien, wie sie die Deutsche
CLL-Studiengruppe im deutschsprachigen Raum durch-
führt, werden diese Fragen in den nächsten Jahren zu
beantworten sein. 
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Summary
Diagnosis and treatment of chronic lymphatic leukaemia
(CLL) are currently undergoing great change. New knowl-
edge of prognosis factors and the numerous new thera-
peutic procedures now available, such as purine analo-
gues, high-dose treatment and monoclonal antibodies
are making major contributions to this progress. As a
consequence, the options for treatment of CLL are consi-
derably more diverse now than a few years ago, and
now include procedures that take into account age and
risk. At the same time, it should be emphasized that
many important questions regarding the treatment of
CLL remain unresolved. It is anticipated that these ques-
tions will be answered over the coming few years by in-
cluding patients in multicentre studies like those being
carried out by the German CLL study group.
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Epidemiology
Chronic lymphatic leukaemia (CLL) is a leukaemic non-
Hodgkin’s lymphoma of the B-cell type. With an annual inci-
dence of 3 cases per 100,000, it is the most common leukaemia
of adulthood in the Western Hemisphere. The median age of
onset is 65–70 years, and while the risk of developing CLL in-
creases with age, no age plateau is reached. About 20% of pa-
tients are younger than 55 years at diagnosis and the propor-
tion of these younger patients has been increasing in recent
years. This is due to earlier diagnosis because of blood counts
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performed for other reasons. Appropriate advice and care for
these younger CLL patients will be of greater significance in
future [1].
The aetiology of CLL is unclear. The possible influence of en-
vironmental factors is under debate, and not yet established.
Genetic factors play a part: children of CLL patients are at
higher risk of contracting CLL or another lymphatic neoplasia
than the normal population [2].
Clinical Symptoms, Disease Progression and Grading 
of Stages
As with other lymphomas, there is no reliable key symptom of
CLL. It is usually asymptomatic in the early stages, the most
common symptom being the occurrence of enlarged lymph
nodes. At an advanced stage, other symptoms, such as reduced
physical and mental stamina, B symptoms and infections, also
occur frequently.
The mean survival period from the time of diagnosis varies
between 2 and more than 10 years, depending on the stage.
The stage classifications of Binet et al. [3] and Rai et al. [4] are
used to estimate the prognosis. Both are based on the extent
of lymphadenopathy, splenomegaly and hepatomegaly mea-
sured by palpation, and anaemia and thrombocytopenia mea-
sured by blood tests. The Binet staging system is simpler and
more widely used throughout Europe. It separates three
major prognostic subgroups (table 1) [5, 6].
However, the Binet staging system alone is not sufficient to
reliably estimate the individual prognosis in the early stages,
especially in younger patients (Binet stage A, Rai stages 0–II).
The following parameters indicate an unfavourable prognosis,
irrespective of the stage [5, 6]:
– a lymphocyte doubling time of less than 12 months,
– increased serum lactate dehydrogenase (LDH) activity,
– elevated serum β2-microglobulin concentration,
– elevated serum thymidine kinase activity,
– increased serum levels of soluble CD23,
– aberrations in chromosomes 11 (11q-) and 17 (17p-),
– lack of somatic hyper-mutations of the immunoglobulin VH-
gene region,
– CD38 positivity of the CLL cells,
– a diffuse or non-nodular bone marrow infiltration.
The relative weighting of these prognosis factors is currently
being determined in studies. A recent interim analysis of the
CLL1 protocol of the German CLL study group suggests that
cytogenetics (11q-, 17p-, trisomy 12), serum thymidine kinase,
and lymphocyte doubling time are more potent than the other
parameters in predicting progression-free survival of early-
stage CLL patients.
Diagnostic and Prognostic Factors
Two examinations are required to diagnose CLL: (1) The eval-
uation of blood count and blood smear and (2) the immune
phenotyping of the leukaemia cells in the peripheral blood
(see A and B, below) [7]. In addition, histopathological evalu-
ation of an enlarged lymph node is important in cases of
doubtful diagnosis (see C, below). Further examinations en-
able early recognition of complications, assessment of the
prognosis or the establishment of the extent of the leukaemia
(D–G, below). 
A. Blood count and blood smear: Permanent elevation of the
absolute lymphocyte count to a value higher than 5 g/l is typi-
cal and is a requirement for the diagnosis of CLL. Typical B-
CLL cells are found in the blood smear − i.e. small lympho-
cytes with a narrow border of cytoplasm and a dense nucleus
with partially aggregated chromatin, and without recognizable
nucleoli. Gumprecht nuclear shadows, found as cell debris, are
characteristic.
B. Immune phenotyping: The immune phenotyping examina-
tion of the lymphocytes from peripheral blood is required for
the diagnosis of CLL. The malignant cells can be classified as
B- or T-cell forms. The evidence of light chain restriction (κ or
λ type) is an important indication of the monoclonal nature of
the cells [8]. The typical antigen sample of CLL cells in flow
cytometry is similar to that of lymphocytes in the region of the
mantle zone of secondary lymphatic follicles. Co-expression
of the antigen CD5, with a weak expression of membrane-re-
sistant immunoglobulins (IgM with or without IgD) and the
expression of B-cell associated membrane antigens, such as
Table 1. Binet staging system and prognosis of CLL [6]
Stage Definition Median 
survival at 
diagnosis, 
years 
A Peripheral blood lymphocytosis > 5000/µl,  >10  
Hb ≥ 10 g/dl, thrombocytes ≥ 100,000/µl, up to 
2 lymph node  regions* involved 
B At least 3 lymph node regions* involved 5  
C Hb < 10 g/dl or thrombocytes < 100,000/µl 2–3  
*Lymph node regions: axillary, inguinal, cervical lymph nodes, as well 
as spleen and liver (maximum 5 regions); palpation is the basis for 
classification. 
Table 2. Typical surface antigen profile of B-CLL
Cell surface antigen Intensity of expression 
Membrane-resistant immunoglobulins weak 
CD5 positive 
CD23 positive 
FMC7 negative 
CD79β negative 
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CD19 and CD23, is characteristic. CD20 is expressed only
weakly, and FMC7 and CD79β are generally not expressed.
The typical surface antigen profile of CLL is summarized in
table 2 [9, 10].
C. Histopathology of an enlarged lymph node: Lymph-node
histology permits the evaluation of the lymph-node architec-
ture, which varies in non-Hodgkin’s lymphomas. This enables a
better distinction of CLL from related entities that express
similar surface markers. It can be particularly difficult to dif-
ferentiate between lympho-plasmocytic lymphoma (immuno-
cytoma), mantle-cell lymphoma and marginal zone lymphoma.
Histological diagnosis provides additional confirmation of this,
and enables the disease to be categorized according to the
REAL or WHO classifications [11]. An impoverished lymph
node architecture, with the loss of nuclear cores and oblitera-
tion of the sinus by infiltrates of small lymphatic cells, is char-
acteristic of the histological appearance of CLL. The predomi-
nant cells are small lymphocytes with aggregated chromatin, a
(mainly) round nucleus and occasionally a small nucleolus.
Larger lymphatic cells are regularly seen (pro-lymphocytes and
paraimmunoblasts), and are usually arranged in foci termed
pseudo-follicles or proliferation centres.
D. Measurement of other laboratory parameters: Serum LDH,
serum electrophoresis to detect paraproteinaemia and serum
immunoglobulins to determine secondary antibody deficiency
should be measured. The Coombs test serves to detect anti-
erythrocyte auto-antibodies. The lymphocyte doubling time
(with observations over at least 3 months) is calculated from
the blood count values. Serum measurements of creatinine,
urea, electrolytes, uric acid, bilirubin and transaminases, as
well as of urine status are also performed before treatment is
started. Serum thymidine kinase and serum β2-microglobulin
are measured to assess the prognosis.
E. Imaging procedures: Following the physical examination of
the patient, and determination of the lymph-node status, an
ultrasound scan of the abdomen is performed and an X-ray of
the thorax taken, in order to assess the involvement of ab-
dominal or intra-thoracic organs and the extent of the lymph-
node enlargements in these regions. With doubtful lym-
phomas, or those causing complications, computer tomogra-
phy of the thorax or the abdomen might also be indicated.
F. Bone marrow examination: Cytological and histological ex-
amination of bone marrow is not necessary for diagnosis [8].
Histological examination of bone marrow allows the extent
and pattern of bone marrow infiltration by CLL (diffuse,
nodular) to be measured. These parameters have prognostic
significance. If unclear cytopenia occurs in the course of the
disease, bone-marrow puncture may explain the aetiology
(leukaemia infiltration, increased megacaryopoesis in autoim-
mune cytopenia, bone-marrow aplasia after chemotherapy).
Bone-marrow puncture with cytological and histological ex-
amination is indicated if there is complete regression of all dis-
ease indications following the treatment: complete remission
(CR) of CLL can be determined only after the bone-marrow
findings are known (see below for criteria used to evaluate
treatment-related progress).
G. Cytogenetics: In more than 80% of CLL patients, confir-
mation of chromosomal aberrations is obtained by interphase
cytogenetics (fluorescence in-situ hybridization, FISH). The
biological significance of such abnormalities is unclear. Cer-
tain aberrations have prognostic value [12]. Deletion of chro-
mosome 13q is the most common and indicates a favourable
prognosis (table 3).
Patients with 17p or 11q deletion have a poorer prognosis
than patients with a normal karyotype or with 13q deletion.
17p and 11q deletions occur almost exclusively in CLL clones
with unmutated genes for the heavy chain of the immunoglob-
ulin (IgH). Patients with the 11q deletion are also clinically
different; they often show marked lymphatic adenopathy and
B symptoms. The implications of these findings for therapeu-
tic decision-making requires clarification in prospective stud-
ies [8, 13].
Therapeutic Indications and Options
The decision to treat is guided by the stage of the disease, the
presence of symptoms and the disease activity. Only patients
in Rai III and IV or Binet C stages should be treated. Patients
in earlier stages should be treated only if symptoms associated
with the disease occur. Symptoms associated with the disease
that justify a decision to treat are: severe B symptoms, a se-
vere loss of performance, and symptoms or threatening com-
plications from spleen or liver enlargement and lymphomas
(e.g. compression of the large abdominal vessels). High dis-
ease activity, which is defined by a lymphocyte doubling time
of less than 6 months or by rapidly growing lymphomas, is also
an indication to treat in the early stages. Autoimmune
haemolytic anaemia or secondary immune thrombocytopenia
with a risk of haemorrhage are treated with corticosteroids;
these signs, as such, are no indication for cytostatic chemo-
therapy. Treatment should not be administered in the early
stages of the disease (Rai stages 0–II, Binet stages A and B)
without symptoms of the disease and without disease activity.
These patients should be only monitored on a regular basis
(‘watch-and-wait’ approach).
Table 3. The most common chromosome aberrations in CLL
Chromosome aberration Frequency, % 
13q deletion 55 
11q deletion 18 
Trisomy 12  16 
17p deletion 7 
6q deletion  6 
Trisomy 8  5 
Trisomy 3  3 
Previously, CLL was treated for palliative reasons, as it was
not possible to achieve lasting complete remissions with con-
ventional therapeutic measures. The development of new
therapeutic options has changed this. Younger patients are
now treated more intensively, with the aim of achieving the
longest possible complete remission, thereby prolonging (dis-
ease-free) survival.
Current and Future Investigations of the German 
CLL Study Group
The German CLL study group (GCLLSG) has set itself the
goal of permanently improving the treatment of CLL. Fore-
most among these concerns are the improvement of quality of
life and the lengthening of the period in which patients are
free of symptoms and disease, and prolongation of life itself.
For this reason, the GCLLSG has developed treatment plans
for all major age and risk groups. In the CLL1 protocol for
patients in Binet stage A, the risk of progression is first deter-
mined. Patients with a high risk of progression (non-nodular
bone-marrow infiltration or lymphocyte doubling time of 
<12 months and elevation of serum thymidine kinase or of
serum β2-microglobulin) are either observed or treated with
fludarabine after randomization. Patients with a low risk of
progression are observed. The CLL1 protocol will be replaced in
2004 by the CLL7 protocol investigating the benefit of a triple
combination chemo-immunotherapy with fludarabine, cy-
clophosphamide and rituximab (FCR) in patients at high risk
(as defined by molecular cytogenetics, elevated serum thymi-
dine kinase, short lymphocyte doubling time, and unmutated
immunoglobulin status) versus a watch-and-wait strategy.
When a clear indication to treat is presented (Binet stage C or
stage B with symptoms), treatment will be initiated, its inten-
sity depending on patient’s age or physical fitness. The CLL4
protocol was designed for patients aged up to 65 years and
compared fludarabine (F) with the combination of fludara-
bine and cyclophosphamide (FC). The trial was closed in July
2003. Preliminary results show that FC is causing more myelo-
suppression but induces twice as many complete remissions as
F alone. The CLL4 protocol was replaced in August 2003 by
the CLL8 protocol, which compares FC versus FC plus ritux-
imab in primary treatment of younger and physically robust
patients with CLL. 
The CLL5 protocol, for patients aged 66 years and above,
compares chlorambucil with fludarabine. It will be replaced in
2004 by the CLL9 protocol testing the benefit of erythropoi-
etin as a supportive treatment in elderly patients treated by a
mild chemotherapy (fludarabine). 
In a relapse situation, patients are treated in the context of
the CLL6 protocol, in which the combination of fludarabine,
cyclophosphamide and mitoxantrone (FCM), which also
achieves a response in patients resistant to fludarabine, is used
for all patients. This protocol tests whether the administration
of granulocyte-stimulating factor (G-CSF) prevents the occur-
rence of severe infections.
The protocols are constantly being extended by innovative
procedures. New substances or combinations are tested in
phase II protocols (CLL2H and CLL2I with alemtuzumab;
CLL2G with CHOP (cyclophosphamide, doxorubicin, vin-
cristine and prednisone) plus rituximab). Experimental treat-
ment procedures, such as high-dose chemotherapy with autol-
ogous stem-cell replacement (CLL3C protocol) or allogeneic
stem-cell transplantation (CLL3X protocol), are also being
tested by the GCLLSG.
Key Elements of Anti-Leukaemia Treatment
A. Conventional Chemotherapy
Chlorambucil: The standard treatment for CLL patients in ad-
vanced stages was previously oral monotherapy with chloram-
bucil [14]. Chlorambucil is an alkylating drug that is usually
well tolerated. Remission rates of up to 40% can be achieved
with chlorambucil, but complete remissions are achieved only
rarely, and partial remissions are of short duration. There is no
advantage in combining chlorambucil with corticosteroids, ex-
cept in autoimmune complications. 
There are two, largely equivalent, methods of administration:
(1) 0.4–0.8 mg/kg body weight on day 1. A dose of 0.4 mg/kg
body weight is administered initially. This dose is increased
from one course to the next by 0.1 mg/kg, depending on the
response and the undesirable effects that occur. If there is an
insufficient therapeutic response, the target dose of 0.8 mg/kg
body weight may be exceeded, taking toxicity into account.
The cycles of treatment are repeated at intervals of 14 days.
(2) 0.07–0.1 mg/kg body weight per day, for a period of 14
days. The treatment cycle can be repeated after a pause of 14
days.
Following successful treatment with chlorambucil, it may be
administered again after 12 months if there is renewed pro-
gression. If the disease progresses on chlorambucil treatment,
or the effect of the treatment lasts for less than 12 months,
other drug treatments should be selected.
Purine analogues: The treatment of CLL has changed greatly
with the introduction of the purine analogues fludarabine and
2-chlordesoxyadenosine (cladribine). Purine analogues are
the first substances that achieve a relatively high rate of com-
plete remission, even as monotherapy drugs [15]. Fludarabine
has been studied more thoroughly than cladribine. Fludara-
bine is administered intravenously at a dose of 25 mg/m2 on
days 1–5, at intervals of 4 weeks. Up to 6 cycles are carried
out.
In primary treatment, the use of fludarabine results in re-
sponse rates of approximately 80%, and around one third of
all patients achieve complete remission [16, 17]. In patients
previously treated with alkylating drugs, the response rates are
between 12 and 55%, and in patients who are resistant to
100 Onkologie 2004;27:97–104 Hallek/Bergmann/Emmerich
Onkologie 2004;27:97–104CLL Diagnosis and Treatment 101
alkylating drugs, between 20 and 40% [18–20]. In the single
phase III study that has been carried out to date, which com-
pared fludarabine directly with chlorambucil in previously un-
treated patients, fludarabine achieved higher response rates
(70 vs. 43%), more complete remissions (27 vs. 3%) and a
longer period of survival free of progression (33 vs. 17
months), but with no clear extension of overall survival [21].
In comparison with more intensive multiple chemotherapy
regimens, such as cyclophosphamide, doxorubicin and pred-
nisone (CAP) or cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP), fludarabine is at least as effective
with regard to response rates and survival free of progression
[22]. In relapses after previous treatment with fludarabine, a
second chemotherapy with fludarabine results in further, high
response rates between 67 and 83% [23].
The main adverse events of purine analogues are myelosup-
pression and lymphocytopenia, with low counts of CD4+-pos-
itive T lymphocytes, although this does not lead to a higher in-
fection rate, in comparison to similar myelosuppressive treat-
ments, such as CAP. However, the spectrum of germs ob-
served is different from that occurring after myelosuppressive
treatment with alkylating agents [24]. In about 1−5% of cases,
autoimmune cytopenia occurs during treatment [25]. A tu-
mour lysis syndrome rarely occurs during treatment with flu-
darabine [26]. The efficacy of cladribine is similar to that of
fludarabine [27–29]. 
Monoclonal antibodies: Monoclonal antibodies bind to de-
fined surface antigens and kill leukaemia cells by various
mechanisms (apoptosis, complement activation, antibody-me-
diated cellular cytotoxicity). The use of monoclonal antibodies
provides an opportunity for treatment of CLL and mainte-
nance of remission. Monoclonal antibodies against CD20 (rit-
uximab) [30] or against CD52 (alemtuzumab, formerly called
Campath-1H) [31] are currently under examination for their
efficacy in clinical studies. Most experience with monoclonal
antibodies is in the treatment of relapses of CLL. In studies to
date, rituximab alone led to partial remissions of short dura-
tion in 20–41% of patients [32, 33]. When dose-intensified rit-
uximab regimens are applied, the response rates may increase
up to 75% [34, 35]. In patients with high leukaemia cell counts
in the peripheral blood, there is a danger of severe undesired
effects, caused not only by the release of cytokines from the
leukaemia cells, but also by the agglutination of leukaemic
cells in small blood vessels [36, 37]. 
Alemtuzumab is directed at CD52, which is expressed by nor-
mal B and T lymphocytes and almost all CLL cells. Undesir-
able effects of alemtuzumab are myelosuppression and T-cell
depletion, which can lead to infectious complications [38].
Alemtuzumab shows its effect particularly in the peripheral
blood and bone marrow. To date, alemtuzumab has been used
primarily in relapses, and results in a response in about 42%
of cases, with a relapse-free interval of >12 months [39].
Therefore, the substance was approved in 2001 for the treat-
ment of relapses after fludarabine failure for CLL. A response
rate of 89% was achieved in primary treatment [40]. The use
of alemtuzumab as a post-remission consolidation therapy has
been studied by the GCLLSG in the CLL4B protocol and by
an Italian pilot study to test the hypothesis that leukaemia
cells can be permanently eliminated in this way [41]. The main
result of this trials is that a post-remission consolidation thera-
py with alemtuzumab can induce complete molecular remis-
sions as demonstrated by real-time quantitative PCR (Wendt-
ner, personal communication). However, the optimal timing
and dosing schedule for alemtuzumab as consolidation thera-
py remains to be determined, as patients with low tumour load
seem to require lower doses of alemtuzumab to achieve opti-
mal effects at low toxicity.
Purine analogue combinations: In order to further improve
treatment with purine analogues, combinations of fludarabine
with cyclophosphamide and/or mitoxantrone were studied, be-
cause they act synergistically in vitro [42]. Amongst those, the
combination of fludarabine and cyclophosphamide is by far the
best studied (table 4). It achieves response rates of more than
80% in pretreated patients [43–47]. The combination of flu-
darabine and epirubicin in a study on previously treated pa-
tients also achieved response rates of over 80%; among these
patients, complete remission was achieved in about 30% [48].
The triple combination of fludarabine, cyclophosphamide and
Author, year [Reference] Combination Patients, n CR, % PR, % OR, %
O’Brien et al., 2001 [45] F 30 mg/m2 and CY 500/350/300 mg/m2 d1–3 93 CLL 16 72 88
Hallek et al., 2001 [44] F 25 mg/m2 and CY 250 mg/m2 d1–3 36 CLL 16 75 91
Frewin et al., 1999 [46] F 25 mg/m2 and CY 250 mg/m2 d1–3 10 NHL 0 50 50
7 CLL 28 43 71
Flinn et al., 2000 [47] F 20 mg/m2 d1–5 and CY 600 mg/m2 d1, 43 NHL 60 32 92
G-CSF 5 mg/kg d8+ 17 CLL 47 53 90
Bosch et al., 2001 [49] F 25 mg/m2 d1–3 and CY 300 mg/m2 d1–3, 60 50, 18 28 78
mitoxantrone 6 mg/m2 d1 molecular 
CR
CR = Complete remission, PR = partial remission, OR = overall response rate, F = fludarabine, CY = cyclophosphamide, 
G-CSF = granulocyte colony stimulating factor.
Table 4. Response
rates of fludarabine
and cyclophosphami-
de combinations
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mitoxantrone induced 50% complete remissions in a study of
relapsed patients [49]. The most common side effects of these
fludarabine combinations are severe infections.
Moreover, the combination of fludarabine with monoclonal
antibodies has yielded very promising results (table 5). The
results obtained so far suggest that there is a synergistic anti-
leukaemic effect of fludarabine and rituximab. The overall re-
sponse rates are between 77 and 95%. Most importantly, the
rate of complete remissions obtained with this combination is
between 20 and 66% except in fludarabine resistant patients
(7%). In particular the combination of fludarabine, cyclophos-
phamide and rituximab induces a high rate of complete remis-
sions of 66% in untreated patients, a result so far unknown in
the primary treatment of CLL [50]. In another study, 104 pa-
tients received fludarabine plus rituximab either simultane-
ously (n = 51; on day 1 of each course) or sequentially (n = 53;
6 courses of fludarabine followed by rituximab for 4 weeks)
[51]. The response was significantly higher if rituximab was
given simultaneously with fludarabine. The overall response
rate was 90 versus 77%, with 47 versus 28% complete remis-
sions (table 5). These results suggest a synergistic mode of ac-
tion of both drugs. Again, the major side effect of this combi-
nation therapy were severe, partially opportunistic infections. 
A combination of alemtuzumab and fludarabine was tested by
Kennedy et al. [54] in 6 patients who were refractory to flu-
darabine. 5 of those responded to this therapy and 1 had a
complete molecular remission. One patient had a pneumonia
caused by Pseudomonas. There was no CMV (cyto megalo
virus) reactivation. Taken together, these results suggest that
the combination of fludarabine with monoclonal antibodies
like rituximab and alemtuzumab is highly promising with re-
gard to its potential to achieve complete molecular remissions. 
Further new drugs: The development of new compounds for
the treatment of CLL is continuing. Currently, there are at
least 20 new compounds in clinical testing [55, 56], most in
phase I or II. These compounds include new chemical agents
(e.g. bryostatin, bendamustin, flavopiridol, depsipeptide, phos-
phodiesterase inhibitors), monoclonal antibodies (e.g. anti-
bodies against CD22, HLA-DR, or radio-conjugated antibod-
ies), as well as genetic therapeutics (e.g. bcl2-antisense
oligonucleotide Genasense® (Genta, Berkeley Heights, NJ,
USA), gene therapy with adenovirus/CD154 vectors). A de-
tailed review of these new agents is beyond the scope of this
manuscript and given elsewhere [55, 56]. 
B: High-Dose Therapy
High-dose treatment with autologous stem-cell transplantation
(SCT): Myeloablative high-dose (chemo)therapy, with subse-
quent autologous SCT, is an interesting experimental treat-
ment for CLL which should be restricted to the framework of
studies [57–59]. Until recently, the often indolent course of the
disease and the high median age of patients contraindicated
such intensive treatment. Because of the relative increase in
the proportion of younger patients (aged <55 years) at high
risk of disease progression, and because of the improvement
in supportive measures, high-dose treatment with autologous
SCT has grown in importance. The GCLLSG has studied this
method of treatment in the CLL3 protocol in which, to date,
more than 300 patients have been included. Mortality due to
treatment is currently 5–10% in the large international studies
and in the CLL3 protocol of the GCLLSG [58]. Because of
the lack of randomised studies, it has not been possible to
evaluate whether this therapeutic approach results in a better
long-term prognosis than conventional chemotherapy. There-
fore, the GCLLSG is now participating in a European ran-
domised phase III trial (CLL3R protocol), which investigates
the early versus delayed use of an autologous SCT after mo-
bilisation following DexaBEAM polychemotherapy. 
High-dose chemotherapy with allogeneic SCT: Because of the
high mortality (between 25 and 50%) [59] associated with
treatment with allogeneic SCT in CLL, the administration of
allogeneic SCT can be recommended only when used in the
framework of studies. Reasons for the high mortality associat-
ed with treatment with allogeneic SCT include the immune
defect associated with CLL, as well as the unfavourable pa-
tient selection (numerous previous treatments). Non-mye-
loablative conditioning protocols could improve the results
[60]. Allogeneic SCT favours the graft-versus-leukaemia ef-
fect, which also plays a part in CLL, as is shown by the suc-
cessful use of donor lymphocyte transfusions [61, 62].
Author, year [Reference] Therapy Patients, n CR, % nPR, % PR, % OR, %
Manero et al., 2001 [52] FC+R alkylator-resistant 15 20 13 33 80
FC+R F-sensitive 60 30 15 33
FC+R F-resistant 27 7 11 41
Byrd et al., 2001 [51] FC+R 51 47 43 90
FC followed by R 53 28 49 77
Wierda et al., 2001 [50] FC+R primary therapy 79 66 14 15 95
Schulz et al., 2002 [53] F+R 29 34 52 90
CR = Complete remission, nPR = nodular partial remission, PR = partial remission, OR = overall response rate, 
FC = fludarabine and cyclophosphamide, R = rituximab.
Table 5. Response
rates of combination
therapies consisting
of fludarabine or 
fludarabine/cyclo-
phosphamide with
rituximab 
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D: Radiation Treatment
In curative treatment plans, radiation treatment is used as
whole-body irradiation in the context of myeloablative radio-
chemotherapy with stem-cell transplantation (see above). As
there are no definitive results from these studies, the use of ra-
diation treatment in this context must be regarded as experi-
mental. Irradiation with a palliative intention may be indicat-
ed in large lymphomas or leukaemia infiltrates, the elimina-
tion of which is of clinical importance. Radiation doses of be-
tween 10 and 40 Gy are used in normal fractionation. An
adequate therapeutic effect is commonly reached at doses of
only 20 Gy. Enlarged spleens causing severe discomfort due to
space encroachment or cases of hypersplenism can be success-
fully treated by radiation therapy. This irradiation should be
carried out in small individual doses (0.3–0.5 Gy, 3× weekly) as
a very rapid fall in thrombocyte and leucocyte counts may
occur otherwise. The total doses are between 3 and 10 Gy.
Supportive Treatment and Treatment of Complications
Infections and autoimmune cytopenias are major complica-
tions of CLL. A detailed description of their management is
beyond the scope of this review, but up-dated reviews on that
issue have been published recently [7, 63]. 
Summary: Consensus Recommendations
During the past decade, much new information on pathogene-
sis, diagnosis and treatment of CLL has emerged. Treatment
options in particular have increased considerably, through the
availability of monoclonal antibodies and the increasing expe-
rience of high-dose treatment, in addition to other develop-
ments. Definitive treatment recommendations cannot there-
fore be given for many circumstances at this time. For exam-
ple, it is at present unclear whether primary chemotherapy of
B-CLL should be with chlorambucil, fludarabine or fludara-
bine combinations. The principal concern must therefore be to
treat all patients in clinical studies.
The GCLLSG has developed a concept for an age- and risk-
adapted treatment of CLL in the framework of clinical stud-
ies. The long-term aim of these efforts is the continuous opti-
misation of treatment in order to achieve higher response
rates, longer periods free of disease, a better quality of life
and, perhaps in the future, a cure for the disease. However,
without documented treatment of patients in clinical studies
aiming at optimisation of therapy no relevant advance in
knowledge will be achieved.
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